These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
203 related articles for article (PubMed ID: 9177216)
1. Transactivation by CIITA, the type II bare lymphocyte syndrome-associated factor, requires participation of multiple regions of the TATA box binding protein. Mahanta SK; Scholl T; Yang FC; Strominger JL Proc Natl Acad Sci U S A; 1997 Jun; 94(12):6324-9. PubMed ID: 9177216 [TBL] [Abstract][Full Text] [Related]
2. Specific complex formation between the type II bare lymphocyte syndrome-associated transactivators CIITA and RFX5. Scholl T; Mahanta SK; Strominger JL Proc Natl Acad Sci U S A; 1997 Jun; 94(12):6330-4. PubMed ID: 9177217 [TBL] [Abstract][Full Text] [Related]
3. Specific interactions with TBP and TFIIB in vitro suggest that 14-3-3 proteins may participate in the regulation of transcription when part of a DNA binding complex. Pan S; Sehnke PC; Ferl RJ; Gurley WB Plant Cell; 1999 Aug; 11(8):1591-602. PubMed ID: 10449590 [TBL] [Abstract][Full Text] [Related]
4. The class II trans-activator CIITA interacts with the TBP-associated factor TAFII32. Fontes JD; Jiang B; Peterlin BM Nucleic Acids Res; 1997 Jun; 25(12):2522-8. PubMed ID: 9171108 [TBL] [Abstract][Full Text] [Related]
5. Transcription factor IIA mutations show activator-specific defects and reveal a IIA function distinct from stimulation of TBP-DNA binding. Ozer J; Bolden AH; Lieberman PM J Biol Chem; 1996 May; 271(19):11182-90. PubMed ID: 8626665 [TBL] [Abstract][Full Text] [Related]
6. Selective use of TBP and TFIIB revealed by a TATA-TBP-TFIIB array with altered specificity. Tansey WP; Herr W Science; 1997 Feb; 275(5301):829-31. PubMed ID: 9012349 [TBL] [Abstract][Full Text] [Related]
7. The MHC class II transactivator (CIITA) requires conserved leucine charged domains for interactions with the conserved W box promoter element. Brown JA; Rogers EM; Boss JM Nucleic Acids Res; 1998 Sep; 26(18):4128-36. PubMed ID: 9722631 [TBL] [Abstract][Full Text] [Related]
8. Mutations on the DNA-binding surface of TATA-binding protein can specifically impair the response to acidic activators in vivo. Lee M; Struhl K Mol Cell Biol; 1995 Oct; 15(10):5461-9. PubMed ID: 7565697 [TBL] [Abstract][Full Text] [Related]
9. Transactivation by the human cytomegalovirus IE2 86-kilodalton protein requires a domain that binds to both the TATA box-binding protein and the retinoblastoma protein. Sommer MH; Scully AL; Spector DH J Virol; 1994 Oct; 68(10):6223-31. PubMed ID: 8083962 [TBL] [Abstract][Full Text] [Related]
10. Transcriptional activation domain of the herpesvirus protein VP16 becomes conformationally constrained upon interaction with basal transcription factors. Shen F; Triezenberg SJ; Hensley P; Porter D; Knutson JR J Biol Chem; 1996 Mar; 271(9):4827-37. PubMed ID: 8617752 [TBL] [Abstract][Full Text] [Related]
11. Altered promoter binding of the TATA box-binding factor induced by the transcriptional activation domain of VP16 and suppressed by TFIIA. Liljelund P; Ingles CJ; Greenblatt J Mol Gen Genet; 1993 Dec; 241(5-6):694-9. PubMed ID: 8264543 [TBL] [Abstract][Full Text] [Related]
12. CIITA leucine-rich repeats control nuclear localization, in vivo recruitment to the major histocompatibility complex (MHC) class II enhanceosome, and MHC class II gene transactivation. Hake SB; Masternak K; Kammerbauer C; Janzen C; Reith W; Steimle V Mol Cell Biol; 2000 Oct; 20(20):7716-25. PubMed ID: 11003667 [TBL] [Abstract][Full Text] [Related]
13. The p53 activation domain binds the TATA box-binding polypeptide in Holo-TFIID, and a neighboring p53 domain inhibits transcription. Liu X; Miller CW; Koeffler PH; Berk AJ Mol Cell Biol; 1993 Jun; 13(6):3291-300. PubMed ID: 8497252 [TBL] [Abstract][Full Text] [Related]
15. Radical mutations reveal TATA-box binding protein surfaces required for activated transcription in vivo. Bryant GO; Martel LS; Burley SK; Berk AJ Genes Dev; 1996 Oct; 10(19):2491-504. PubMed ID: 8843200 [TBL] [Abstract][Full Text] [Related]
16. Promoter-specific activation defects by a novel yeast TBP mutant compromised for TFIIB interaction. Virbasius CM; Holstege FC; Young RA; Green MR Curr Biol; 2001 Nov; 11(22):1794-8. PubMed ID: 11719223 [TBL] [Abstract][Full Text] [Related]
17. Functional interaction of the c-Myc transactivation domain with the TATA binding protein: evidence for an induced fit model of transactivation domain folding. McEwan IJ; Dahlman-Wright K; Ford J; Wright AP Biochemistry; 1996 Jul; 35(29):9584-93. PubMed ID: 8755740 [TBL] [Abstract][Full Text] [Related]
18. Taf(II) 250 phosphorylates human transcription factor IIA on serine residues important for TBP binding and transcription activity. Solow S; Salunek M; Ryan R; Lieberman PM J Biol Chem; 2001 May; 276(19):15886-92. PubMed ID: 11278496 [TBL] [Abstract][Full Text] [Related]
19. Effects of activation-defective TBP mutations on transcription initiation in yeast. Kim TK; Hashimoto S; Kelleher RJ; Flanagan PM; Kornberg RD; Horikoshi M; Roeder RG Nature; 1994 May; 369(6477):252-5. PubMed ID: 8183347 [TBL] [Abstract][Full Text] [Related]
20. Evidence for functional interaction between the HIV-1 Tat transactivator and the TATA box binding protein in vivo. Veschambre P; Simard P; Jalinot P J Mol Biol; 1995 Jul; 250(2):169-80. PubMed ID: 7608968 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]